Sabatolimab (MBG453), a novel antibody directed against TIM-3, is under investigation in a phase Ib trial (NCT03066648) with or without PDR001 (anti PD-1) in combination with HMAs in AML patients [23]. The gene discussed is PDCD1; the disease is acute myeloid leukemia.